$1.5 Billion Accelerated Share Repurchase Launched by United Therapeutics
Summary
United Therapeutics has initiated two accelerated share repurchase (ASR) agreements totaling $1.5 billion with Citi, executing a significant portion of its recently authorized $2 billion buyback program. This follows the company's announcement earlier today of the new $2 billion stock repurchase authorization. The $1.5 billion ASR represents a material capital return to shareholders, approximately 6.5% of the company's market capitalization. This move is expected to reduce the outstanding share count, providing a positive catalyst for earnings per share and potentially supporting the stock price, which is currently near its 52-week high. Traders will monitor the completion of these ASRs through Q2 and Q3 2026 and any further deployment of the remaining $500 million under the buyback authorization.
At the time of this announcement, UTHR was trading at $529.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.2B. The 52-week trading range was $266.98 to $537.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.